Navigation Links
Transposagen and Cellular Dynamics International Cross-License Technologies for Induced Pluripotent Stem Cells
Date:1/5/2011

LEXINGTON, Ky., Jan. 5, 2011 /PRNewswire/ -- Transposagen Biopharmaceuticals, Inc. (Transposagen), a leader in genetic modification technology, announced today that it has entered into a non-exclusive license agreement with Cellular Dynamics International (CDI), the world's largest producer of human induced pluripotent stem (iPS) cell lines and tissue cells for drug discovery and safety.

The license agreement allows CDI to use Transposagen's piggyBac technology in the creation of its products. The piggyBac technology is a highly versatile non-viral method for genetic engineering and stable transgene expression. "We are pleased to be partnering with CDI," said Dr. Eric Ostertag, President and CEO of Transposagen. "Like Transposagen, their products are revolutionizing the drug discovery process."

"CDI is committed to providing human cells derived from iPS cells in the quality, purity, and quantity required by customers, enabling them to concentrate on generating reliable, reproducible, and predictive data and not on creating the cells themselves," said Bob Palay, CDI CEO and chairman of the board. "Toward that end, CDI continues to seek and license in useful technologies, such as piggyBac, that may help improve our manufacturing capabilities." In addition to its iCell™ Cardiomyocytes product line, CDI is planning to launch hepatocytes, neurons, and endothelial cells in the next year.  

The two companies have also agreed to a research and development collaboration.  Transposagen was granted a research license to any cell or product developed by CDI that uses piggyBac for its creation.  Transposagen, the worldwide leader in genetically modified rats, may use CDI's cells to develop "humanized rats," rats that contain organs predominantly consisting of human-derived cells.  Transposagen is developing products expected to improve drug discovery and development by more accurately predicting human response to potential therapeutics at the pre-clinical stage.

About Transposagen BiopharmaceuticalsTransposagen Biopharmaceuticals, Inc., a Lexington, KY based company, is the worldwide leader in the creation of unique genetically modified rat models.  The company's signature products, TKO™ Knockout Rat Models and TGEM™ Rat Models, mimic human diseases and are used for drug discovery and development research. The company also creates custom transgenic rat models to customer specifications. For more information or to request a custom rat model, visit www.transposagenbio.com.

About Cellular Dynamics International, Inc.Cellular Dynamics International, Inc. (CDI) is a leading developer and marketer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPSC technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cells from the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based private equity fund. CDI's facilities are located in Madison, Wisconsin.  See www.cellulardynamics.com.Contact:Jack Crawford145 Graham Ave.ASTeCC Bldg., Suite A217Lexington, KY 40506859-428-8561
'/>"/>

SOURCE Transposagen Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transposagen Announces Exclusive License with Charles River Laboratories for p53 and Bcrp TGEM™ Knockout Rat Models
2. Largest Acellular Dermal Allografts for Abdominal Wall Repair Now Available From MTF
3. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
4. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
5. Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio
6. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
7. Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening
8. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
9. Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing
10. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
11. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Aesthetic Devices - Medical Devices Pipeline ... report, "Aesthetic Devices - Medical Devices Pipeline Assessment, 2015" ... stage. This report is prepared using ... by GlobalData,s team of industry experts. *Note: Certain ... based on the availability and relevance of data in ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
(Date:2/8/2016)... 8, 2016  Echo Therapeutics, Inc. (Nasdaq: ... focused on non-invasive continuous glucose monitoring (CGM) ... that it will host a webcast and ... at 9:00 a.m. Eastern Time to provide ... strategy, advancements in its CGM system, and ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie ... celebrates the beginning of a new charity campaign. As part of their ongoing ... Advocates (CASA). In the belief that children deserve a voice, and in the ...
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley ... into Canada to provide its range of unique and advantaged protective solutions ... City that will provide bilingual customer service and marketing support. A new distribution ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... relationship-marketing firm, announced today that nominations will be accepted February 8, 2016 ... Awards. , Awards include the Information Security Executive® of the Year, ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... than 50% lower incidence rate of type 2 diabetes in the GrassrootsHealth cohort ... is time to make a change in public health,” states Carole Baggerly, Director ...
(Date:2/8/2016)... ... ... The schedule is now online for the largest and most ... being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to give the ... chronic illness in children. , Very recent articles have cited 1 child in 20 ...
Breaking Medicine News(10 mins):